Eli Lilly and Company (LLY) Given Average Recommendation of “Hold” by Brokerages
Eli Lilly and Company (NYSE:LLY) has been assigned a consensus recommendation of “Hold” from the twenty-three ratings firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $88.36.
Several brokerages have recently commented on LLY. BMO Capital Markets restated a “sell” rating and issued a $71.00 target price on shares of Eli Lilly and in a research report on Thursday. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price for the company in a research report on Monday, July 17th. Jefferies Group LLC restated a “buy” rating and issued a $93.00 target price on shares of Eli Lilly and in a research report on Thursday, June 22nd. Deutsche Bank AG restated a “buy” rating and issued a $91.00 target price (up from $90.00) on shares of Eli Lilly and in a research report on Monday, July 17th. Finally, Morgan Stanley restated a “hold” rating and issued a $86.00 target price on shares of Eli Lilly and in a research report on Friday, September 15th.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the sale, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders sold 590,000 shares of company stock worth $48,551,300. 0.20% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Acrospire Investment Management LLC grew its holdings in Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the period. MPS Loria Financial Planners LLC acquired a new stake in Eli Lilly and in the second quarter valued at approximately $128,000. San Francisco Sentry Investment Group CA acquired a new stake in Eli Lilly and in the second quarter valued at approximately $129,000. Heritage Trust Co acquired a new stake in Eli Lilly and in the first quarter valued at approximately $135,000. Finally, Point72 Asia Hong Kong Ltd grew its holdings in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after purchasing an additional 1,239 shares during the period. 75.72% of the stock is currently owned by institutional investors.
Shares of Eli Lilly and (NYSE LLY) traded up 0.64% during mid-day trading on Friday, reaching $85.54. 3,506,102 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $80.84 and a 200-day moving average price of $82.02. The stock has a market cap of $90.24 billion, a PE ratio of 37.01 and a beta of 0.34. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $86.72.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.86 EPS. On average, analysts predict that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/30/eli-lilly-and-company-lly-given-average-recommendation-of-hold-by-brokerages.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.